New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
10:25 EDTABBV, ABBV, ABBV, RHHBY, RHHBY, RHHBY, PFE, PFE, PFE, PBYI, PBYI, PBYI, NVS, NVS, NVS, MDVN, MDVN, MDVN, LLY, LLY, LLY, JNJ, JNJ, JNJ, GSK, GSK, GSK, CLVS, CLVS, CLVS, CLDX, CLDX, CLDX, BMRN, BMRN, BMRN, AZN, AZN, AZN, AMGN, AMGN, AMGN, TSRO, TSRO, TSROLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide updates on breast cancer, in conjunction with the upcoming ASCO Annual Meeting, on an Analyst/Industry conference call to be held on May 20 at 11 am.
News For ABBV;AMGN;AZN;BMRN;CLDX;CLVS;GSK;JNJ;LLY;MDVN;NVS;PBYI;PFE;RHHBY;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
May 14, 2015
06:04 EDTLLYEli Lilly, Sanford-Burnham to investigate immunological therapies
Subscribe for More Information
05:52 EDTCLVS, AZNMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
19:17 EDTPFEHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
19:12 EDTPBYIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Paragon Offshore (PGN), up 10.3%... Shake Shack (SHAK), up 10%... Vipshop Holdings (VIPS), up 6.7%. ALSO HIGHER: Vascular Biogenics (VBLT), up 12.8% and Oncothyreon (ONTY), up 15.5% after release of ASCO presentation data. DOWN AFTER EARNINGS: Identiv (INVE), down 10.3%... Sphere 3D (ANY), down 11.3%... VOXX International (VOXX), down 8.1%. ALSO LOWER: Puma Biotechnology (PBYI), down 21.8% after Neratinib data published in ASCO abstract... Karyopharm Therapeutics (KPTI), down 1.2% after ASCO presentation data released... Gevo (GEVO), down 11.4% after filing to sell common stock and warrants.
18:37 EDTPBYIBiopharmaceutical stocks volatile after release of ASCO presentation data
After the market close, the American Society of Clinical Oncology, or ASCO, provided public access to 5,000 cancer drug trial research abstracts ahead of the society's 51st annual meeting from May 29 to June 2 in Chicago, Illinois. In after-hours trading, a number of biopharmaceutical stocks were active, including Vascular Biogenics (VBLT) and Oncothyreon (ONTY), which rose 13% and 14.9%, respectively, and Puma Biotechnology (PBYI) and Karyopharm Therapeutics (KPTI), which fell 23.9% and 14.8%, respectively.
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:59 EDTTSROTESARO to present seven abstracts at ASCO
Subscribe for More Information
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
17:47 EDTPBYIPuma Biotechnology down 24% after Neratinib data published in ASCO abstract
Subscribe for More Information
17:28 EDTCLDXCelldex to present data from Phase 2 ReACT study of Rintega at ASCO
Celldex Therapeutics announced that several clinical programs, including the Phase 2 ReACT study of Rintega in patients with recurrent glioblastoma, or GBM, will be presented at the 2015 American Society of Clinical Oncology, or ASCO, Annual Meeting in Chicago. The ReACT presentation will include final analysis of progression-free survival at 6 months, or PFS6, and current data on overall survival and other endpoints. Data contained in the published abstract were from an analysis in October 2014. Data to be presented in the oral session will include comprehensive data from the study through March.
17:24 EDTAZNAstraZeneca to update progress with immuno-oncology pipeline at ASCO
AstraZeneca and MedImmune, the company’s global biologics research and development arm, will demonstrate rapid progress with their combination-focused oncology pipeline at the American Society of Clinical Oncology, or ASCO, Annual Meeting, May 29-June 2. 61 scientific abstracts will be presented at the meeting, reinforcing the significant progress in immuno-oncology through combination therapies and innovative companion diagnostics.
17:23 EDTCLVSClovis announces ASCO presentations including TIGER-X study update
Subscribe for More Information
17:19 EDTPFEPfizer, Merck KGaA to present data at ASCO for avelumab
Subscribe for More Information
17:17 EDTAMGNAmgen to present key results in solid tumor, hematologic malignancy treatments
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
13:43 EDTPFEHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
13:12 EDTABBVSen. Sanders urges VA to break patents on Gilead hepatitis C drugs
Subscribe for More Information
11:38 EDTGSKGlaxoSmithKline downgraded to Neutral from Buy at UBS
Subscribe for More Information
07:31 EDTPFEHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:07 EDTGSKGSK, Emergent BioSolutions, Oxford initiate Prime Boost study of Ebola vaccine
A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara, or MVA, Ebola Zaire vaccine candidate, or MVA EBOZ, as a prime-boost to GlaxoSmithKline's (GSK) Chimp Adenovirus type 3, or ChAd3, Ebola vaccine candidate. The study, being conducted by the clinical research group of Professor Adrian Hill of the Jenner Institute, has received regulatory approval to begin from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, or MHRA. The phase 1 study has a planned enrollment of 38 volunteers of which 6 will receive MVA EBOZ only while the other 32 will receive ChAd3-EBO-Z prime followed by MVA EBOZ boost. Emergent BioSolutions (EBS) manufactured the supply of MVA EBOZ to be used in this phase 1 study, which is being conducted in the U.K. with support from the Wellcome Trust and the U.K. Department for International Development.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use